Description: OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
Home Page: www.olixpharma.com
#1014 Gwanggyo Ace Tower1, 17
Suwon-si,
16226
South Korea
Phone:
82 3 1779 8400
Officers
| Name | Title |
|---|---|
| Mr. Dong-Ki Lee | CEO & Director |
| Mr. Sun-Woo Hong | VP & Director of Research and Director |
| Ms. Shin Young Park Ph.D. | Sr. VP of Gen. Devel. |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 75.5773 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 67 |